MAM
BMY.RT

Melqart Asset Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Melqart Asset Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,700,000
Closed -$3.24M – 179
2020
Q4 		$3.24M Buy
4,700,000
+3,150,900
+203% +$6.71M 0.24% 73
2020
Q3 		$3.48M Sell
1,549,100
-300,900
-16% -$859K 0.39% 52
2020
Q2 		$6.62M Sell
1,850,000
-475,000
-20% -$1.71M 0.82% 26
2020
Q1 		$8.84M Buy
2,325,000
+525,900
+29% +$1.73M 0.87% 24
2019
Q4 		$5.42M Buy
+1,799,100
New +$4.68M 0.45% 33

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Melqart Asset Management's BMY.RT Position: Q1 2021 in Review

Melqart Asset Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 4,700,000 shares — an estimated $3.24M sold.

Melqart Asset Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $8.84M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Melqart Asset Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Melqart Asset Management sold 4,700,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $3.24M.
  • Melqart Asset Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Melqart Asset Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $8.84M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Melqart Asset Management's 13F filing for Q1 2021, filed 17 May 2021.